Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site

• Published in: Cell Vol. 162; no. 5; pp. 1090 - 1100
• Main Authors: Kanekiyo, Masaru, Bu, Wei, Joyce, M. Gordon, Meng, Geng, Whittle, James R.R., Baxa, Ulrich, Yamamoto, Takuya, Narpala, Sandeep, Todd, John-Paul, Rao, Srinivas S., McDermott, Adrian B., Koup, Richard A., Rossmann, Michael G., Mascola, John R., Graham, Barney S., Cohen, Jeffrey I., Nabel, Gary J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.08.2015
• Subjects: animal models; Animals; Antibodies, Neutralizing - immunology; complement; Crystallography, X-Ray; Drug Design; Female; glycoproteins; Herpesvirus 4, Human; Herpesvirus Vaccines - chemistry; Herpesvirus Vaccines - genetics; Herpesvirus Vaccines - immunology; Herpesvirus Vaccines - isolation & purification; Human gammaherpesvirus 4; immunity; Macaca fascicularis; Mice; Mice, Inbred BALB C; nanoparticles; Nanoparticles - chemistry; Nanoparticles - ultrastructure; neoplasms; neutralization; neutralizing antibodies; Primates; Receptors, Complement 3d - chemistry; Receptors, Complement 3d - immunology; Recombinant Proteins - chemistry; Recombinant Proteins - genetics; Recombinant Proteins - immunology; Recombinant Proteins - isolation & purification; vaccine development; vaccines; viruses

Epstein-Barr virus (EBV) represents a major global health problem. Though it is associated with infectious mononucleosis and ∼200,000 cancers annually worldwide, a vaccine is not available. The major target of immunity is EBV glycoprotein 350/220 (gp350) that mediates attachment to B cells through c...